Skip Navigation



NDT Plus Advance Access published online on June 2, 2008
NDT Plus, doi:10.1093/ndtplus/sfn063
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/5/296    most recent
sfn063v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kheda, M. F.
Right arrow Articles by Szerlip, H. M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Two cases of iodixanol-induced pancreatitis

Mufaddal F. Kheda and Harold M. Szerlip

Section of Nephrology, Medical College of Georgia, Augusta, GA 30912, USA

Correspondence: Harold M. Szerlip, BI 5072, 1120 15th Street, Augusta, GA 30912, USA. Tel: +1-706-721-2055; Fax: +1-706-721-8631; E-mail: hszerlip@mcg.edu

Key Words: adverse events • hemodialysis • pancreatitis • radio-contrast agents

Received for publication April 30, 2008. Accepted for publication May 10, 2008.

The first 10% of the full text of this article appears below.


   Introduction
 
Because of the escalating number of patients on dialysis and the increased use of vascular access surveillance, more and more hemodialysis patients are undergoing angiographic procedures for angioplasty and thrombectomy of their vascular access. Such procedures expose these patients to radiographic contrast agents (RCAs). Even though, newer low-osmolar and iso-osmolar nonionic RCAs, which are associated with fewer adverse effects, are increasingly used, these agents can still cause complications. We report two cases of pancreatitis in end-stage renal disease (ESRD) patients, associated with intravenous use of the iodixanol. Although RCAs have been reported to exacerbate experimentally induced pancreatitis in animals [1] and possibly prolong the clinical course of acute pancreatitis in humans [3,4], there are no documented cases of intravascular RCA inducing pancreatitis in humans.

In the cases below, the RCAs used are iodixanol-320 . . . [Full Text of this Article]


   Case report
 
Case 1
Case 2

   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?